Rick Miller
Analyst, Cantor Fitzgerald
Replay available
ADMA Biologics Inc (NASDAQ: ADMA) Q1 2025 earnings conference call, held 2025-05-07. Replay captured from the company's public earnings webcast.

Analyst, Cantor Fitzgerald
Chief Financial Officer and Treasurer
President and Chief Executive Officer
Analyst, Mizuho Securities
Analyst, Raymond James
Good afternoon and welcome to ADMA Biologics first quarter 2025 financial results and business update conference call on Wednesday, May 7, 2025. At this time, all participants are in the listen-only mode. There will be a question and answer session to follow. Please be advised that this call is being recorded at the company's request and will be available on the company's website approximately two hours following the end of the call. At this time, I would like to introduce the company. Please go ahead. Welcome, everyone, and thank you for joining us this afternoon to discuss ADMA Biologics financial results for the first quarter of 2025 and recent corporate updates. I'm joined today by Adam Grossman, President and Chief Executive Officer, and Brad Tate, Chief Financial Officer and Treasurer. During today's call, Adam will provide some introductory comments and provide an update on corporate progress, and then Brad will provide an overview of the company's first quarter 2025 financial results. Finally, Adam will then provide some brief summary remarks before opening up the call for questions. Earlier today, we issued a press release detailing the first quarter 2025 financial results and summarized certain achievements in recent corporate updates. The release is available on our website at www.admobiologics.com. Before we begin our formal comments, I'll remind you that we will be making forward-looking assertions during today's call that represent the company's intentions, expectations, or beliefs concerning future events, which constitute forward-looking statements for the purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to factors, risks, and uncertainties, such as those deta...